Allychem Co., Ltd., Dalian, China

Allychem Co., Ltd.,Dalian, China founded in 2004, registered capital of 66 million RMB, located in the Dagushan chemical industrial park, Jinzhou New District, Dalian, China.

Allychem committed to the development and production of organoboronic acids & derivatives and chiral compounds from milligram to multi-kilogram scale that offers a complete range of services to pharmaceutical, fine chemical and electronic material companies around the world.

Allychem is the top manufacturer of organoboronic acids in China, the world's largest diboron production base.

Since establishment, Allychem has a series of coupling reagent with proprietary intellectual property and industrialized synthesis technology of chiral compounds, applied for 50 national invention patents, 12 has been authorized, and undertake 12 projects from national and postdoctoral institution.

Research & Development

ISO 9001:2015 is certified by DNV. GL Since 2006

Safety & Health

We hav established 59 SOPs about HSE management according to the requirements of national safety supervision system.

Ø Safety production and training

Ø Risk assessment and control

Ø Equipment maintenance and management

Ø Occupational disease hazards and prevention

Have passed work safety standardization since 2012.

Have passed work safety standardization since 2012.

Safety training to new employee

Regular training to old employee

Daily production safety inspection

Regular equipment overhaul

Full staff insurance

Regular occupational health check

Environment

Environmental protection and waste control

Waste gas is recovered by the absorption towel.

Waste water is treated in Allychem biochemical treating system, discharged after reaching the standard.

Waste solid and waste solvents are transferred to the third party with a professional qualification.

BBChem Co., Ltd.

- 100% hold by Allychem. 

- RMB 110 million registered capital. 

- Located in Songmudao Chemical Industry Park, Dalian. 

- 62000m²

- 60km away from current site.

- Trial operation in September, 2020.